The lack of uniformity in follow-up time, as well broad period over which implants took place (2020–2023), may have resulted in differences in management, including that SGLT2 inhibitors and sacubitril/valsartan to replace ACEi/ARB in NYHA class III HF patients did not become part of societal guideline recommendations until 2022 [13]. Here, SLC5A2 is linked to hydrops fetalis.